Miracor Medical Systems GmbH Successfully Completes Enrollment of 30 Patients in a Safety and Feasibility Study Using its PICSO® System to Treat Severe Heart Attack Patients Post-Primary PCI

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VIENNA--(BUSINESS WIRE)--Miracor Medical Systems GmbH announced today that 30 patients have been successfully treated with no device-related adverse events using its PICSO® (Pressure-controlled Intermittent Coronary Sinus Occlusion) System designed to improve myocardial perfusion following primary PCI (Percutaneous Coronary Intervention, or angioplasty). (Click here for video animation of PICSO®.) The study enrollment was completed in several European centers of excellence with Prof. Jan Piek at the Academic Medical Center in Amsterdam as the Principal Investigator.

Help employers find you! Check out all the jobs and post your resume.

Back to news